首页> 美国卫生研究院文献>British Journal of Cancer >Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer
【2h】

Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer

机译:乳腺癌患者原发肿瘤的血管生成和缺氧可预测淋巴结转移中的血管生成和缺氧

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hypoxia and angiogenesis are important factors in breast cancer progression. Little is known of hypoxia and angiogenesis in lymph node metastases of breast cancer. The aim of this study was to quantify hypoxia, by hypoxia-induced marker expression levels, and angiogenesis, by endothelial cell proliferation, comparing primary breast tumours and axillary lymph node metastases. Tissue sections of the primary tumour and a lymph node metastasis of 60 patients with breast cancer were immunohistochemically stained for the hypoxia-markers carbonic anhydrase 9 (CA9), hypoxia-inducible factor-1α (Hif-1α) and DEC-1 and for CD34/Ki-67. Endothelial cell proliferation fraction (ECP%) and tumour cell proliferation fraction (TCP%) were assessed. On haematoxylin–eosin stain, the growth pattern and the presence of a fibrotic focus were assessed. Hypoxia-marker expression, ECP% and TCP% in primary tumours and in lymph node metastases were correlated to each other and to clinico-pathological variables. Median ECP% and TCP% in primary tumours and lymph node metastases were comparable (primary tumours: ECP%=4.02, TCP%=19.54; lymph node metastases: ECP%=5.47, TCP%=21.26). ECP% correlated with TCP% (primary tumours: r=0.63, P<0.001; lymph node metastases: r=0.76, P<0.001). CA9 and Hif-1α expression were correlated (primary tumours P=0.005; lymph node metastases P<0.001). In primary tumours, CA9 and Hif-1α expression were correlated with DEC-1 expression (P=0.05), presence of a fibrotic focus (P<0.007) and mixed/expansive growth pattern (P<0.001). Primary tumours and lymph node metastases with CA9 or Hif-1α expression had a higher ECP% and TCP% (P<0.003); in primary tumours, mixed/expansive growth pattern and fibrotic focus were characterised by higher ECP% (P=0.03). Furthermore, between primary tumours and lymph node metastases a correlation was found for ECP%, TCP%, CA9 and Hif-1α expression (ECP% r=0.51, P<0.001; TCP r=0.77, P<0.001; CA9 and Hif-1α P<0.001). Our data demonstrate that the growth of breast cancer lymph node metastases is angiogenesis dependent and that angiogenesis and hypoxia in the primary tumour predict angiogenesis and hypoxia in the lymph node metastases. Together with previous findings in breast cancer liver metastases, which grow in 96% of cases angiogenesis independently, these data suggest that both the intrinsic growth characteristics and angiogenic potential of breast cancer cells and the site-specific tumour microenvironment determine angiogenesis and hypoxia in breast cancer.
机译:缺氧和血管生成是乳腺癌进展的重要因素。乳腺癌淋巴结转移的低氧和血管生成知之甚少。这项研究的目的是通过低氧诱导的标志物表达水平来定量低氧,并通过内皮细胞增殖来定量血管生成,比较原发性乳腺肿瘤和腋窝淋巴结转移。对60例乳腺癌患者的原发性肿瘤组织切片和淋巴结转移进行了免疫组织化学染色,检测缺氧标记物碳酸酐酶9(CA9),缺氧诱导因子-1α(Hif-1α)和DEC-1以及CD34 / Ki-67。评估内皮细胞增殖分数(ECP%)和肿瘤细胞增殖分数(TCP%)。在苏木精-伊红染色上,评估了生长方式和纤维化病灶的存在。低氧标志物表达,ECP%和TCP%在原发性肿瘤和淋巴结转移中彼此相关,并与临床病理变量相关。原发肿瘤和淋巴结转移的中位ECP%和TCP%相当(原发肿瘤:ECP%= 4.02,TCP%= 19.54;淋巴结转移:ECP%= 5.47,TCP%= 21.26)。 ECP%与TCP%相关(原发肿瘤:r = 0.63,P <0.001;淋巴结转移:r = 0.76,P <0.001)。 CA9和Hif-1α的表达相关(原发肿瘤P = 0.005;淋巴结转移P <0.001)。在原发性肿瘤中,CA9和Hif-1α的表达与DEC-1的表达相关(P = 0.05),纤维化灶的存在(P <0.007)和混合/扩张的生长方式(P <0.001)。 CA9或Hif-1α表达的原发肿瘤和淋巴结转移具有较高的ECP%和TCP%(P <0.003);在原发性肿瘤中,混合/扩展生长方式和纤维化病灶的特征是较高的ECP%(P = 0.03)。此外,在原发肿瘤和淋巴结转移之间,ECP%,TCP%,CA9和Hif-1 α表达之间存在相关性(ECP% r = 0.51, P <0.001; TCP r = 0.77, P <0.001; CA9和Hif-1 αP <0.001)。我们的数据表明乳腺癌淋巴结转移的生长是血管生成依赖性的,并且原发性肿瘤中的血管生成和低氧预示着淋巴结转移中的血管生成和低氧。连同先前在96%的血管生成病例中独立发生的乳腺癌肝转移的发现,这些数据表明乳腺癌细胞的内在生长特征和血管生成潜力以及特定部位的肿瘤微环境都决定了乳腺癌的血管生成和缺氧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号